CL2008002349A1 - Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. - Google Patents

Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.

Info

Publication number
CL2008002349A1
CL2008002349A1 CL2008002349A CL2008002349A CL2008002349A1 CL 2008002349 A1 CL2008002349 A1 CL 2008002349A1 CL 2008002349 A CL2008002349 A CL 2008002349A CL 2008002349 A CL2008002349 A CL 2008002349A CL 2008002349 A1 CL2008002349 A1 CL 2008002349A1
Authority
CL
Chile
Prior art keywords
cells
antibody
human
molecule
encodes
Prior art date
Application number
CL2008002349A
Other languages
English (en)
Inventor
Elinborg Ostermann
Karl-Heinz Heider
Eric Borges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002349(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2008002349A1 publication Critical patent/CL2008002349A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MOLECULA DE ANTICUERPO QUE SE UNE A CD37 HUMANO Y QUE SE OBTIENE A PARTIR DE A) UN ANTICUERPO MONOCLONAL MURINO QUE ESTA DEFINIDO POR I) UNA CADENA PESADA ARIABLE QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS MOSTRADA EN SEQ ID NO: 2; Y II) UNA CADENA LIGERA VARIABLE QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS MOSTRADA EN SEQ ID NO: 4, O A PARTIR DE UN B) ANTICUERPO NO HUMANO QUE RECONOCE EL MISMO EPITOPO DE CD37 HUMANO QUE EL ANTICUERPO DEFINIDO EN A) O QUE RECONOCE UN EPITOPO QUE ESTA CERCA DE O SE SUPERPONE CON DICHO EPITOPO; EN QUE DICHA MOLECULA DE ANTICUERPO ES UN ANTICUERPO QUIMERICO O HUMANIZADO.
CL2008002349A 2007-08-09 2008-08-08 Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. CL2008002349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114128 2007-08-09

Publications (1)

Publication Number Publication Date
CL2008002349A1 true CL2008002349A1 (es) 2009-10-23

Family

ID=38925567

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008002349A CL2008002349A1 (es) 2007-08-09 2008-08-08 Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
CL2011001592A CL2011001592A1 (es) 2007-08-09 2011-06-24 Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08).
CL2012002329A CL2012002329A1 (es) 2007-08-09 2012-08-22 Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2011001592A CL2011001592A1 (es) 2007-08-09 2011-06-24 Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08).
CL2012002329A CL2012002329A1 (es) 2007-08-09 2012-08-22 Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08)

Country Status (37)

Country Link
US (7) US20100189722A1 (es)
EP (3) EP2241577A1 (es)
JP (3) JP5325216B2 (es)
KR (1) KR101593403B1 (es)
CN (4) CN102276724A (es)
AR (2) AR071242A1 (es)
AU (1) AU2008285590B2 (es)
BR (2) BRPI0823331A2 (es)
CA (1) CA2693464C (es)
CL (3) CL2008002349A1 (es)
CO (1) CO6251371A2 (es)
CY (1) CY1117101T1 (es)
DK (1) DK2178915T3 (es)
EA (2) EA027499B1 (es)
EC (2) ECSP109946A (es)
ES (1) ES2555202T3 (es)
HK (1) HK1220708A1 (es)
HR (1) HRP20160009T1 (es)
HU (1) HUE026221T2 (es)
IL (1) IL202645A (es)
MA (1) MA32665B1 (es)
ME (1) ME02300B (es)
MY (1) MY157555A (es)
NZ (2) NZ600022A (es)
PE (3) PE20120259A1 (es)
PH (1) PH12014501812A1 (es)
PL (1) PL2178915T3 (es)
PT (1) PT2178915E (es)
RS (1) RS54359B1 (es)
SG (1) SG190657A1 (es)
SI (1) SI2178915T1 (es)
TN (1) TN2010000068A1 (es)
TW (2) TW201512220A (es)
UA (2) UA105445C2 (es)
UY (1) UY31275A1 (es)
WO (1) WO2009019312A2 (es)
ZA (1) ZA200908758B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
EA027502B1 (ru) * 2009-12-23 2017-08-31 Зиниммуне Гмбх Антитела против flt3 и способы их применения
NO331080B1 (no) 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120107317A1 (en) * 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
WO2012135740A2 (en) * 2011-04-01 2012-10-04 Immunogen, Inc. Cd37-binding molecules and immunoconjugates thereof
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
CN109276713A (zh) * 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
SG11201405766SA (en) * 2012-03-30 2014-10-30 Immunogen Inc Methods for increasing efficacy of cd37-based therapy
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US8992915B2 (en) * 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
JP2015517512A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd37抗体の更なる薬剤との併用
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
EP3008089A1 (en) * 2013-06-14 2016-04-20 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with chlorambucil
US9925273B2 (en) 2013-08-01 2018-03-27 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
US9291244B2 (en) 2014-01-17 2016-03-22 Ford Global Technologies, Llc Nine speed automatic transmission
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
JP6979877B2 (ja) 2015-06-08 2021-12-15 デビオファーム インターナショナル, エス. アー. 抗cd37イムノコンジュゲートおよび抗cd20抗体の組み合わせ
SI3124976T1 (sl) * 2015-07-28 2018-12-31 F. Hoffmann-La Roche Ag Izboljšan test bakterijskih endotoksinov za določanje endotoksinov
US11104740B2 (en) 2015-08-28 2021-08-31 Debiopharm International, S.A. Antibodies and assays for detection of CD37
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN110461363B (zh) 2017-03-16 2024-04-02 综合医院公司 靶向cd37的嵌合抗原受体
WO2018178396A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP7278978B2 (ja) * 2017-06-27 2023-05-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化asgr1座位を含む非ヒト動物
CA3099928A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Cd37特異的キメラ抗原レセプター
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
EP4021579A1 (en) * 2019-08-30 2022-07-06 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
CN118119408A (zh) * 2021-10-18 2024-05-31 第一三共株式会社 抗cd37抗体-药物缀合物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
AU643189B2 (en) * 1988-09-06 1993-11-11 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3457962B2 (ja) 1991-08-14 2003-10-20 ジェネンテク,インコーポレイテッド 特定Fcεレセプターのための免疫グロブリン変異体
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2001506967A (ja) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999043713A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2004016753A2 (en) 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4652414B2 (ja) 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド FcRnとの変化した結合を有するFc変異体
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
EP1931709B1 (en) * 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
TWI428444B (zh) 2005-10-12 2014-03-01 Morphosys Ag 由全長人類HuCAL GOLD-衍生之對人類CD38有特異性之治療抗體之產生及鑑定
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AU2008287195A1 (en) 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
CA2731255C (en) 2008-07-21 2018-06-05 David M. Goldenberg Structural variants of antibodies for improved therapeutic characteristics
CN102271708A (zh) 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 Cd37免疫治疗联合疗法及其用途
US20120189618A1 (en) 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US8992915B2 (en) * 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
JP2015517512A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd37抗体の更なる薬剤との併用
EP3008089A1 (en) 2013-06-14 2016-04-20 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with chlorambucil

Also Published As

Publication number Publication date
EA201000274A1 (ru) 2010-10-29
CA2693464C (en) 2017-10-24
DK2178915T3 (en) 2015-12-14
UA105445C2 (en) 2014-05-12
ECSP11009946A (es) 2011-09-30
EP2178915A2 (en) 2010-04-28
CA2693464A1 (en) 2009-02-12
CN102276724A (zh) 2011-12-14
TW201512220A (zh) 2015-04-01
CL2012002329A1 (es) 2012-12-21
AU2008285590A1 (en) 2009-02-12
ECSP109946A (es) 2010-04-30
US20100189722A1 (en) 2010-07-29
JP2010535483A (ja) 2010-11-25
PH12014501812B1 (en) 2016-10-24
JP5325216B2 (ja) 2013-10-23
EP2178915B1 (en) 2015-10-14
US20140004110A1 (en) 2014-01-02
EA201200994A1 (ru) 2012-12-28
HK1220708A1 (zh) 2017-05-12
TWI535733B (zh) 2016-06-01
US20140010808A1 (en) 2014-01-09
PE20090499A1 (es) 2009-05-18
PL2178915T3 (pl) 2016-03-31
EP2562187A1 (en) 2013-02-27
WO2009019312A3 (en) 2009-04-30
CL2011001592A1 (es) 2012-02-17
RS54359B1 (en) 2016-04-28
SG190657A1 (en) 2013-06-28
JP5238000B2 (ja) 2013-07-17
EP2562187B1 (en) 2019-03-27
BRPI0815369A2 (pt) 2013-03-12
CO6251371A2 (es) 2011-02-21
JP2014039541A (ja) 2014-03-06
KR20100054791A (ko) 2010-05-25
PH12014501812A1 (en) 2016-10-24
AR071242A1 (es) 2010-06-09
WO2009019312A2 (en) 2009-02-12
TN2010000068A1 (en) 2011-09-26
TW200916478A (en) 2009-04-16
UA103005C2 (en) 2013-09-10
CY1117101T1 (el) 2017-04-05
CN101815725A (zh) 2010-08-25
MY157555A (en) 2016-06-30
US20180186876A1 (en) 2018-07-05
AU2008285590B2 (en) 2014-08-14
ME02300B (me) 2016-06-20
CN103396490A (zh) 2013-11-20
US9078879B2 (en) 2015-07-14
PE20140196A1 (es) 2014-03-19
SI2178915T1 (sl) 2016-01-29
BRPI0823331A2 (pt) 2013-07-30
CN105273086A (zh) 2016-01-27
NZ600022A (en) 2013-11-29
KR101593403B1 (ko) 2016-02-12
PE20120259A1 (es) 2012-04-04
US20160137729A1 (en) 2016-05-19
US20210230271A1 (en) 2021-07-29
JP2011004758A (ja) 2011-01-13
PT2178915E (pt) 2016-02-04
US9932399B2 (en) 2018-04-03
EP2241577A1 (en) 2010-10-20
ZA200908758B (en) 2010-08-25
HUE026221T2 (en) 2016-05-30
EA027499B1 (ru) 2017-08-31
HRP20160009T1 (hr) 2016-02-12
MA32665B1 (fr) 2011-10-02
US20110165153A1 (en) 2011-07-07
UY31275A1 (es) 2009-03-31
AR107902A2 (es) 2018-06-28
IL202645A (en) 2016-03-31
NZ583713A (en) 2012-07-27
ES2555202T3 (es) 2015-12-29
IL202645A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
PE20141162A1 (es) Anticuerpos anti-il-23
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
CY1118303T1 (el) Συγκεκριμενο για διασταυρουμενα-ειδη δι-συγκεκριμενο αντισωμα μονης-αλυσου psmaxcd3
BRPI0812091A2 (pt) Método para fabricar uma proteína policlonal recombinante
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20121034A1 (es) Anticuerpos anti-factor d humanizados
AR052889A1 (es) Anticuerpos contra interleuquina-1 beta
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20091172A1 (es) Anticuerpos bivalentes biespecificos
AR064333A1 (es) Anticuerpo anti-tslp de diseno
PE20140979A1 (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
NZ741567A (en) Antibodies for treatment of cancer expressing claudin 6
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
AR093186A1 (es) Proteinas de union al antigeno cd27l
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
EA201001762A1 (ru) Антитела и способы их получения